IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang
Natura:	Articolo
Lingua:	English
Pubblicazione:	MDPI AG 2024-06-01
Serie:	Pharmaceutics
Soggetti:	glioma angiogenesis indoleamine 2,3-dioxygenase 1 tryptophan depletion general control nonderepressible 2
Accesso online:	https://www.mdpi.com/1999-4923/16/7/870

Documenti analoghi

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
di: V. A. Kozlov, et al.
Pubblicazione: (2017-07-01)

On the nonredundant roles of TDO2 and IDO1
di: Paolo ePuccetti
Pubblicazione: (2014-10-01)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
di: Ganiyu Olatunbosun Arinola, et al.
Pubblicazione: (2023-01-01)

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
di: Chiara Suvieri, et al.
Pubblicazione: (2024-11-01)

Tryptophan-degrading enzymes in tumoral immune resistance
di: Nicolas van Baren, et al.
Pubblicazione: (2016-11-01)

Association of Indoleamine 2,3-Dioxygenase (IDO) Activity with Outcome after Cardiac Surgery in Adult Patients
di: Andrea Stieger, et al.
Pubblicazione: (2024-06-01)

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
di: Peng X, et al.
Pubblicazione: (2022-08-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
di: Cemil Bilir, M.D., et al.
Pubblicazione: (2017-07-01)

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders
di: Adrian Mor, et al.
Pubblicazione: (2024-07-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
di: Eleonora Panfili, et al.
Pubblicazione: (2023-04-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
di: Chuan Zhou, et al.
Pubblicazione: (2020-03-01)

Tumor Microenvironment‐Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic Immunosuppression
di: Mengna Wang, et al.
Pubblicazione: (2025-02-01)

Pharmacological Targets of Kaempferol Within Inflammatory Pathways—A Hint Towards the Central Role of Tryptophan Metabolism
di: Stefanie Hofer, et al.
Pubblicazione: (2020-02-01)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
di: Florent Peyraud, et al.
Pubblicazione: (2022-01-01)

The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism
di: Dietmar Fuchs, et al.
Pubblicazione: (2010-08-01)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T Cells in Mammals
di: Ursula eGrohmann, et al.
Pubblicazione: (2015-02-01)

Systemic tryptophan homeostasis
di: Simon Klaessens, et al.
Pubblicazione: (2022-09-01)

DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota
di: Li-Ping Zhao, et al.
Pubblicazione: (2023-01-01)

1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
di: Huihan Ma, et al.
Pubblicazione: (2020-09-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
di: Thiara Manuele Alves de Souza, et al.
Pubblicazione: (2022-04-01)

Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
di: Karl Savonije, et al.
Pubblicazione: (2023-05-01)

IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
di: Hongmei Liu, et al.
Pubblicazione: (2022-07-01)

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
di: Concetta Elisa Onesti, et al.
Pubblicazione: (2019-07-01)

Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
di: Pilvi Maliniemi, et al.
Pubblicazione: (2017-03-01)

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
di: Dongquan Xiang, et al.
Pubblicazione: (2023-06-01)

Kynurenines as a Novel Target for the Treatment of Malignancies
di: Adrian Mor, et al.
Pubblicazione: (2021-06-01)

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
di: Jacques C. Mbongue, et al.
Pubblicazione: (2015-09-01)

The role of tryptophan in Chlamydia trachomatis persistence
di: Li Wang, et al.
Pubblicazione: (2022-08-01)

Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents
di: Hui Wen, et al.
Pubblicazione: (2019-06-01)

Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism
di: Heinz Zoller, et al.
Pubblicazione: (2015-06-01)

The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
di: Alex A. Kashi, et al.
Pubblicazione: (2019-07-01)

Tryptophan feeding of the IDO1-AhR axis in host-microbial symbioses
di: Teresa eZelante, et al.
Pubblicazione: (2014-12-01)

Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1
di: Wentao Zhang, et al.
Pubblicazione: (2023-05-01)

Dexamethasone Induces the Expression and Function of Tryptophan-2-3-Dioxygenase in SK-MEL-28 Melanoma Cells
di: Marta Cecchi, et al.
Pubblicazione: (2021-03-01)

Tryptophan metabolite-regulated Treg responses contribute to attenuation of airway inflammation during specific immunotherapy in a mouse asthma model
di: Qi Hu, et al.
Pubblicazione: (2020-08-01)

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources
di: Ying Tan, et al.
Pubblicazione: (2022-11-01)

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
di: Dyah L. Dewi, et al.
Pubblicazione: (2017-02-01)

PEG-Poly(1-Methyl-<span style="font-variant: small-caps">l</span>-Tryptophan)-Based Polymeric Micelles as Enzymatically Activated Inhibitors of Indoleamine 2,3-Dioxygenase
di: George Lo Huang, et al.
Pubblicazione: (2019-05-01)

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
di: Andrea Botticelli, et al.
Pubblicazione: (2020-07-01)

Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation
di: Isabell Adam, et al.
Pubblicazione: (2018-12-01)